Menu Close

Let BC PharmaCare hear “Your Voice” on tildrakizumab (Ilumya) for the treatment of moderate to severe plaque psoriasis

image of a loudspeaker icon

Tildrakizumab (Ilumya™) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about tildrakizumab for the treatment of moderate to severe plaque psoriasis.

You can give input if you are a B.C. resident and have plaque psoriasis, a caregiver to someone with plaque psoriasis, or if your group represents people who live with plaque psoriasis.

If you would like our help in providing your input, you can email your comments to feedback@jointhealth.org or call us at 604-974-1366. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Tuesday, January 14 so that we may submit the questionnaire in time for the deadline.

The submission deadline is midnight on January 15, 2020. Patients and caregivers may give their input directly through the links below.

Please click here to let BC PharmaCare hear Your Voice. Or, go to the following links:

  • To view the information sheet for tildrakizumab for the treatment of moderate to severe plaque psoriasis: click here
  • For the Patient Questionnaire:click here
  • For the Caregiver Questionnaire:click here
  • For the Patient Group Questionnaire:click here (Patient groups are required to register their name with the Ministry of Health before making their submission.)